Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): Results of an international individual patient data survey (IPDS)

BJU International

Volumn 112, Issue 6, 2013, Pages 742-750

  Witjes, J Alfred ^a   Palou, Joan ^b   Soloway, Mark ^c   Lamm, Donald ^d   Kamat, Ashish M ^e   Brausi, Maurizio ^f   Persad, Raj ^g   Buckley, Roger ^h   Colombel, Marc ⁱ   Böhle, Andreas ^j  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f AUSL Modena   (Italy)

^g BRISTOL UROLOGICAL INSTITUTE   (United Kingdom)

^h NORTH YORK GENERAL HOSPITAL   (Canada)

ⁱ UNIVERSITÉ LYON 1   (France)

^j HELIOS AGNES KARLL HOSPITAL   (Germany)

more..

Author keywords

bacillus Calmette Gu rin (BCG); guideline adherence; non muscle invasive bladder cancer (NMIBC); physician survey; practice gaps

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; CYSTECTOMY; DRUG USE; EUROPE; FEMALE; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; NORTH AMERICA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION;

BACILLUS CALMETTE-GUÉRIN (BCG); GUIDELINE ADHERENCE; NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC); PHYSICIAN SURVEY; PRACTICE GAPS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; BCG VACCINE; EUROPE; FEMALE; GUIDELINE ADHERENCE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NORTH AMERICA; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84884282390     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12012     Document Type: Article

References (30)

1. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-477
2. Babjuk M, Oosterlinck W, Sylvester R, et al. European Association of Urology guidelines on non-muscle invasive bladder cancer (TaT1 and CIS). Arnhem: European Association of Urology, 2012. Available at: http://www.uroweb.org/gls/ pdf/05-TaT1-Bladder-Cancer.pdf Accessed 10 September 2012
3. Fernandez-Gomez J, Madero R, Solsona E, et al. Club Urológico Español de Tratamiento Oncológico. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol 2011; 60: 423-430
4. Brausi M, Witjes JA, Lamm D, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011; 186: 2158-2167
5. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J,. European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-314
6. American Urological Association. Guidelines for the Management of Non-Muscle Invasive Bladder Cancer (Stages Ta, T1, and TIS): 2007 Update. Linthicum, MD: AUA, 2007: Available at: http://www.auanet.org/content/clinical- practice-guidelines/clinical-guidelines/main-reports/bladcan07/chapter1.pdf Accessed 25 October 2012
7. Hall MC, Chang SS, Balbagni G, et al. Guidelines for the management of non-muscle invasive bladder cancer (stages Ta, T1, and TIS): 2007 update. J Urol 2007; 178: 2314-2330
8. Chamie K, Saigal CS, Lai J, et al. The Urologic Diseases in America Project. Quality of care in patients with bladder cancer: a case report? Cancer 2012; 118: 1412-1421
9. Chamie K, Saigal CS, Lai J, et al. The Urologic Diseases in America Project. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 2011; 117: 5392-5401
10. Huang GJ, Hamilton AS, Lo M, Stein JP, Penson DF,. Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the Surveillance, Epidemiology and End Results program 2003 patterns of care project. J Urol 2008; 180: 520-524
11. Gontero P, Oderda M, Altieri V, et al. Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the Vesical Antiblastic Therapy Italian Study. Urol Int 2011; 86: 19-24
12. Nielsen ME, Smith AB, Pruthi RS, et al. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey. BJU Int 2012; 110: 967-972
13. Joudi FN, Smith BJ, O'Donnell MA, Konety BR,. Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. Urology 2003; 62: 1083-1088
14. O'Leary MP, Gee WF, Holtgrewe HL, et al. 1999 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of incontinence and bladder cancer, and impact of managed care. J Urol 2000; 164: 1311-1316
15. Böhle A, Jocham D, Bock PR,. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169: 90-95
16. Böhle A, Bock PR,. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology 2004; 63: 682-686
17. Han RF, Pan JG,. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006; 67: 1216-1223
18. Hinotsu S, Akaza H, Naito S, et al. Maintenance therapy with bacillus Calmette-Guérin (BCG) Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumor (TURBT) for non-muscle-invasive transitional cell carcinoma of the bladder. BJU Int 2010; 108: 187-195
19. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-1129
20. Sylvester RJ, van der Meijden AP, Lamm DL,. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-1970
21. Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage TaT1 urothelial carcinoma of the bladder. Eur Urol 2010; 57: 766-773
22. Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 247-256
23. Shelley MD, Mason MD, Kynaston H,. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev 2010; 36: 195-205
24. Herr HW,. Is maintenance bacillus Calmette-Guérin really necessary? Eur Urol 2008; 54: 971-973
25. Witjes JA, Palou J, Soloway M, et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol 2008; 7 (Suppl.): 667-674
26. Lamm D, Persad R, Colombel M, Brausi M,. Maintenance bacillus Calmette-Guérin: the standard of care for the prophylaxis and management of intermediate- and high-risk non-muscle invasive bladder cancer. Eur Urol 2010; 9 (Suppl.): 715-734
27. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV, EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guérin for Ta, T1 bladder tumors is not associated with increase toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003; 44: 429-434
28. Brausi MA, Oddens JR, Sylvester RJ, et al. Bacillus Calmette- Guérin: one-third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer [1050]. Poster presentation at the 27th Annual EAU Congress. Paris, France; 27 February 2012
29. Rischmann P,. Improving compliance of BCG immunotherapy: practical approaches to managing side-effects. Eur Urol 2006; 5 (Suppl.): 660-662
30. Rodríguez F, Palou J, Martínez R, et al. [Practical guideline for the management of adverse events associated with BCG installations]. Arch Esp Urol 2008; 61: 591-596